The American Academy of Pediatrics (AAP) has just updated their safe infant sleep environment recommendations, citing evidence that infants should sleep in the same room with their parents, ideally for the first full year of life, but at the very least for the first 6 months.
The FDA has approved class-wide labeling changes for prescription testosterone products regarding risks of abuse and dependence associated with testosterone and other anabolic androgenic steroids (AASs).
For decades, clinicians relied on a limited number of drugs, including sulfonylureas and metformin, to help patients with type 2 diabetes. However, in the past 20 years, an increasing number of glucose-lowering drugs for diabetes treatment have become available.
The FDA has awarded 21 grants for new clinical trial research worth more than $23 million to be spent over the next 4 years on the development of products for patients with rare diseases.
How many times have you seen increasing doses of sleep medications prescribed to your patients?
A great need exists in the United States for readily accessible naloxone, and pharmacists have a vital role to play to increase its availability and safe use.
The incidence of heart failure is increasing as the world’s population ages and the rates of other, often comorbid, diseases (eg, diabetes, heart disease, obesity) increase.
The FDA has approved Lilly’s Lartruvo (olaratumab injection), in combination with –doxorubicin, for the treatment of soft tissue sarcoma (STS) in adults.